B. Biswas, Nikhil S Ghadyalpatil, Shekar Patil, Amol Patel, S. Ganguly, Anvesh Rathore, B. Guleria, Cpalli Firdouse Tarannum, Joydeep Ghosh, Mary Sravani Kondapally, Ravi Thippeswamy, Shashidhara Haragadde Poppa Reddy, Somnath Roy
{"title":"印度ALK重组晚期非小细胞肺癌患者二线及二线以上使用lorlatinib的安全性和有效性的真实世界研究--多中心病历回顾研究(ROSELAND)","authors":"B. Biswas, Nikhil S Ghadyalpatil, Shekar Patil, Amol Patel, S. Ganguly, Anvesh Rathore, B. Guleria, Cpalli Firdouse Tarannum, Joydeep Ghosh, Mary Sravani Kondapally, Ravi Thippeswamy, Shashidhara Haragadde Poppa Reddy, Somnath Roy","doi":"10.3332/ecancer.2024.1667","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"28 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND)\",\"authors\":\"B. Biswas, Nikhil S Ghadyalpatil, Shekar Patil, Amol Patel, S. Ganguly, Anvesh Rathore, B. Guleria, Cpalli Firdouse Tarannum, Joydeep Ghosh, Mary Sravani Kondapally, Ravi Thippeswamy, Shashidhara Haragadde Poppa Reddy, Somnath Roy\",\"doi\":\"10.3332/ecancer.2024.1667\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":502597,\"journal\":{\"name\":\"ecancermedicalscience\",\"volume\":\"28 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ecancermedicalscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3332/ecancer.2024.1667\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2024.1667","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND)